Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07000253 | Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma(OMEC-5) | recruiting | Phase 2 | 290 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 3 | Sep 10, 2026 | clinicaltrials |
| NCT07161869 | Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)(POELH-III) | recruiting | — | 250 | Erasmus Medical CenterOTHER |
| 1 |
| Sep 10, 2026 |
| clinicaltrials |
| NCT07676162 | A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer | recruiting | Phase 3 | 300 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07677774 | GPC3-Targeted PET/CT in Hepatocellular Carcinoma | recruiting | N/A | 40 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07733427 | Evaluating the Effectiveness of AIT in the Treatment of Pain Related to Pancreatic Cancer(PIT) | not yet recruiting | N/A | 40 | Clinique BizetOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07780838 | Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma | recruiting | Phase 2 | 29 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811453 | Liver Transplantation for Non-Resectable Colorectal Liver Metastases Without Local Treatment Options(GTO-001) | not yet recruiting | N/A | 260 | Charite University, Berlin, GermanyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811752 | Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer | recruiting | Phase 2 | 28 | Shanghai Chest HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812805 | SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors | recruiting | Phase 1 | 100 | SK Life Science, Inc.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT07813572 | ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular | not yet recruiting | Phase 3 | 600 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07814014 | Real-world Insight Into Systemic Therapies for HCC: Single-center Study(HCC) | recruiting | — | 1,000 | Mansoura UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07814066 | A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07814326 | Feasibility of the Loop Brush EUS-FNA for Characterization of Pancreatic Cysts: Pilot Clinical Investigation(PCLoop-Pilot) | not yet recruiting | N/A | 8 | Urban ArneloOTHER_GOV | 1 | Sep 10, 2026 | clinicaltrials |
| NCT01660971 | Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT02962063 | Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer | active not recruiting | Phase 1 / Phase 2 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT02968810 | Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 2 | Sep 9, 2026 | clinicaltrials |
| NCT03212274 | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations | active not recruiting | Phase 2 | 89 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03803553 | Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | active not recruiting | Phase 3 | 400 | Massachusetts General HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04104672 | A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies(ARC-8) | completed | Phase 1 | 196 | Arcus Biosciences, Inc.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04899908 | Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases | recruiting | Phase 2 | 134 | Brigham and Women's HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05039892 | Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma | not yet recruiting | Phase 2 | 50 | 3D Medicines (Beijing) Co., Ltd.INDUSTRY | 0 | Sep 9, 2026 | clinicaltrials |
| NCT05685602 | CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer | suspended | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05706558 | Retrospective Review of Esophageal Cancer at MSKCC | recruiting | — | 4,000 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05715931 | Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma | active not recruiting | Phase 2 | 30 | Yu jirenOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05968326 | A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC(IMCODE003) | active not recruiting | Phase 2 | 260 | Genentech, Inc.INDUSTRY | 10 | Sep 9, 2026 | clinicaltrials |
| NCT06037980 | CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence(PURITY) | recruiting | Phase 2 / Phase 3 | 300 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06175845 | Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma(ACTICCA-2) | recruiting | N/A | 130 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06253871 | A Phase 1/1b Study of IAM1363 in HER2 Cancers | recruiting | Phase 1 | 383 | Iambic Therapeutics, IncINDUSTRY | 8 | Sep 9, 2026 | clinicaltrials |
| NCT06440005 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Angiex, Inc.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06501482 | Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI(IRIMAD) | recruiting | Phase 3 | 254 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06548412 | CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers | recruiting | Phase 1 / Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06578559 | Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC(BRICKET) | active not recruiting | Phase 2 | 16 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06597721 | ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours | recruiting | Phase 1 | 210 | Adcendo ApSINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
| NCT06625775 | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 392 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 6 | Sep 9, 2026 | clinicaltrials |
| NCT06696768 | Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer | recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06699836 | CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen(CLOVER) | active not recruiting | Phase 2 | 66 | CytoDyn, Inc.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06897644 | Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.(PANThEON) | recruiting | Phase 3 | 340 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07147231 | Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07272083 | New Diagnostic Criteria in the Evaluation Response to Ablation Treatment of Hepatocellular Carcinoma Nodules(CEUS_LR_TRA) | recruiting | — | 200 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07341217 | Chemo Brain Prehab Project(CHEMOBRAIN) | recruiting | N/A | 86 | Dr. Chris GaffneyOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07409987 | TENS and Compression for Established Oxaliplatin-Induced Peripheral Neuropathy | completed | N/A | 140 | Cumhuriyet UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07539311 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers(RAINFOL-09) | recruiting | Phase 2 | 160 | GenmabINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
| NCT07549412 | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) | recruiting | Phase 3 | 1,020 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 16 | Sep 9, 2026 | clinicaltrials |
| NCT07689201 | A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib | recruiting | Phase 2 | 24 | GlaxoSmithKlineINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07805369 | A Phase 1 Study of DEM301 in Participants With Metastatic Colorectal Cancer | not yet recruiting | Phase 1 | 60 | DEM BioPharma, Inc.INDUSTRY | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07808671 | A Decision Support Tool for Pancreatic Cancer Screening -Aim 2 | not yet recruiting | N/A | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07808879 | Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma Localization(HBED-CC-PEG6-E) | recruiting | N/A | 20 | Peking Union Medical College HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07809074 | Mindfulness and Self-Compassion Intervention for Ostomy Patients Due to Colorectal Cancer on Loneliness (MSC-OP)(MSC-OP) | not yet recruiting | N/A | 20 | The Hong Kong Polytechnic UniversityOTHER | 0 | Sep 9, 2026 | clinicaltrials |
Data updated 21 days agoSource updated Sep 10, 2026source: clinicaltrials